Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.
about
Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assayAntiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus ErythematosusThe Role of TLR4 on B Cell Activation and Anti-β2GPI Antibody Production in the Antiphospholipid SyndromeAntiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome."New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndromeTreatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches.Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome.Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers.Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome.The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.Epigenetics and Systemic Lupus Erythematosus: Unmet Needs.Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.Current status and future prospects for the treatment of antiphospholipid syndrome.The antiphospholipid syndrome: from pathophysiology to treatment.The Laboratory Diagnosis of the Antiphospholipid Syndrome.The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays: A Large, Retrospective Study at a Coagulation Reference Laboratory.Genetic Risk Factors in Venous Thromboembolism.Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools.Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops.Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients.An Integrated Soft Computing Approach to Hughes Syndrome Risk Assessment.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome.Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome.A importância de reconhecer a síndrome antifosfolípide na medicina vascular.Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications.
P2860
Q26739950-F28BF80E-0611-4ECD-BD13-2C48C81B2A03Q26766428-A8018368-35D1-4CA8-977E-A74DF187CF04Q28069430-18680D28-EEE4-4141-A470-3486E6B4BAF5Q33435408-244DF809-4E1A-47DF-9B72-ABF143A59F8BQ35250419-07A346FC-CC02-453D-A912-5D7617F3DC14Q35621012-1621DD93-2F20-45CA-8ECB-43FB850719D4Q36037794-A1F961FB-C0AF-4CD5-9821-6A5386A73C81Q36923241-D374C73E-6913-4A05-8A7D-DAEB0D3B4EC4Q38258585-979D6D5B-1838-4216-855A-4A4BDF435440Q38362118-1664E0D5-D73A-4EBD-A92E-DE7DBEC9A172Q38553346-A5F0F72B-9693-474E-B8B9-F96B64A6C3D4Q38657043-F2D5891B-CB1D-4307-BEBD-E10285E03F17Q38818425-621A7620-C1B3-43FF-A62A-E9081B2BA5D9Q38873953-3A66FE76-6B62-4B8D-A555-2A1530CB1327Q39134202-30EC3591-9D51-42B5-B557-A3A4A4CCE09EQ39318344-084B2DF9-540C-46B0-84C1-490C58707F7EQ40577579-FC21F83A-8600-4EAF-8203-28E6730859B5Q40649226-CDE74966-FF1A-4B06-8EB9-16D6B4DAB480Q41103646-8CEBFA6D-EA95-453C-8C25-1B8538D93ADCQ47550799-1ABD6C39-D7EF-410A-B2C0-721FAE848D7CQ47685633-892D2A5B-70CE-4BA8-AE25-99BEE5DFFA56Q47997867-7D0A8785-60A8-40EF-916B-862FFD6E182FQ47998109-3C7955EE-7EAE-4EA0-9F77-FE35E734D44BQ48243949-137587E7-1944-468C-B251-22664248ACCAQ50025567-1E5CFA95-8F70-47BD-A491-6A74A9EB4A53Q55279180-7143C644-A030-4A35-B38D-FCC1F5B908DDQ55407136-443B7C92-CF8B-446B-BAE9-663985CE7AF9
P2860
Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antiphospholipid syndrome in 2 ...... ayers and emerging biomarkers.
@ast
Antiphospholipid syndrome in 2 ...... ayers and emerging biomarkers.
@en
type
label
Antiphospholipid syndrome in 2 ...... ayers and emerging biomarkers.
@ast
Antiphospholipid syndrome in 2 ...... ayers and emerging biomarkers.
@en
prefLabel
Antiphospholipid syndrome in 2 ...... ayers and emerging biomarkers.
@ast
Antiphospholipid syndrome in 2 ...... ayers and emerging biomarkers.
@en
P2860
P50
P356
P1476
Antiphospholipid syndrome in 2 ...... ayers and emerging biomarkers.
@en
P2093
Francesca Rovelli
P2860
P2888
P356
10.1186/AR4549
P577
2014-01-01T00:00:00Z
P5875
P6179
1048540190